Nasdaq:US$15.00 (-0.25) | HKEX:HK$23.38 (-0.58) | AIM:£2.20 (+0.01)
Search
Announcements
1234
5
6789101112131415161718
found Documents: 881
Announcements & Press Releases, Regulatory Notice | 12 May 2023

HUTCHMED Announces Board of Directors and Board Committee Membership
Hong Kong, Shanghai & Florham Park, NJ  — Friday, May 12, 2023: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:​HCM, HKEX:​13) refers to its announcement on May 10, 2023 of the appointment of Professor Solange P
Read More
HKEX Announcement (PDF)LSE RNS Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 10 May 2023

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committees
Hong Kong, Shanghai & Florham Park, NJ  — Wednesday, May 10, 2023: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:​HCM, HKEX:​13) today announces that that Professor Solange Peters is appointed as an Independent
Read More
LSE RNS Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 2 May 2023

Monthly Return
HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 28 Apr 2023

Total Voting Rights
LSE RNS Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 21 Apr 2023

Vesting of awards under the Long Term Incentive Plan
Hong Kong, Shanghai & Florham Park, NJ — Friday, April 21, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) announces that the non-performance based awards granted under the Long Term Incentive Plan (“LTIP”) on Apr
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 18 Apr 2023

HUTCHMED Announces NDA Acceptance in China for Fruquintinib in Second-Line Gastric Cancer
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, April 18, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that its New Drug Application (“NDA”) for fruquintinib in combination with paclitaxe
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 12 Apr 2023

HUTCHMED Highlights Presentations at American Association for Cancer Research Annual Meeting 2023
Hong Kong, Shanghai & Florham Park, NJ — Wednesday, April 12, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM, HKEX: 13) today announces that new and updated clinical and non-clinical data related to five HUTCHMED investigation
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Event, Regulatory Notice | 11 Apr 2023

Annual General Meeting 2023
Date: Friday, May 12, 2023 Time: 5:00 pm Hong Kong Time (10:00 am London Time) Location:1st Floor, Harbour Grand Kowloon, 20 Tak Fung Street, Hung Hom, Kowloon, Hong Kong  
Read More
Circular - Annual General MeetingForm of ProxyOnline AGM User Guide (PDF)2022 Annual ReportLetter to new registered shareholders and reply formNotification letter to registered holders and request formNotification letter to non-registered holders and request formAnnouncement - Notice of Annual General Meeting2022 Sustainability Report
Announcements & Press Releases, Group | 11 Apr 2023

2022 Annual Report and Notice of Annual General Meeting
Hong Kong, Shanghai, & Florham Park, NJ — Tuesday, April 11, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that its 2022 Annual Report together with the Notice of Annual General Meeting and the Form
Read More
HKEX Announcement (PDF)LSE RNS Announcement (PDF)HKEX - Notice of Annual General Meeting
Announcements & Press Releases, Regulatory Notice | 11 Apr 2023

Intended Retirement of Independent Non-executive Director
Hong Kong, Shanghai & Florham Park, NJ  — Tuesday, April 11, 2023: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:​HCM, HKEX:​13) today announces that Dr Karen Jean Ferrante has informed the Company that she wou
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 4 Apr 2023

Monthly Return
HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 4 Apr 2023

HUTCHMED Initiates Registration Phase Enrollments of HMPL-453 for IHCC and Savolitinib for Gastric Cancer following NMPA Consultations
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, April 4, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has consulted the China National Medical Products Administration (“NMPA”) and reach
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 31 Mar 2023

Total Voting Rights
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 31 Mar 2023

HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer
— NDA supported by data from global Phase III FRESCO-2 study in the U.S., Europe, Japan and Australia along with data from Phase III FRESCO study conducted in China — — FRESCO-2 showed fruquintinib treatment reduced the risk of death by 34% in
Read More
HKEX Announcement (PDF)LSE RNS Announcement (PDF)
Announcement Topics, Oncology / Immunology | 14 Mar 2023

HUTCHMED Announces Closing of Fruquintinib License to Takeda Outside China
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, March 14, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM, HKEX:​13) today announces that, further to its announcement on January 23, 2023 and following the completion of
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Group | 13 Mar 2023

HUTCHMED Confirms No Assets Held at Silicon Valley Bank
Hong Kong, Shanghai & Florham Park, NJ — Monday, March 13, 2023: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today confirms that it does not have any exposure to Silicon Valley Bank (“SVB”) or Si
Read More
View Press Release (PDF)
Announcement Topics, Regulatory Notice | 8 Mar 2023

Director’s Share Dealing
Hong Kong, Shanghai & Florham Park, NJ — Wednesday, March 8, 2023: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM; SEHK:13) has received notifications that Mr Johnny Cheng, Executive Director and Chief Financial
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 6 Mar 2023

Vesting of awards under the Long Term Incentive Plan
Hong Kong, Shanghai & Florham Park, NJ — Monday, March 6, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) announces that following the announcement of the 2022 annual results of HUTCHMED on February 28, 2023, the foll
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 1 Mar 2023

Monthly Return
HKEX Announcement (PDF)
Announcement Topics, Regulatory Notice | 28 Feb 2023

Publication of Form 20-F
Hong Kong, Shanghai & Florham Park, NJ: Tuesday, February 28, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today published the Form 20-F for the financial year ended December 31, 2022.  This is available for viewing
Read More
HKEX Announcement (PDF)
Announcements & Press Releases, Group | 28 Feb 2023

HUTCHMED Reports 2022 Full Year Results and Provides Business Updates
Landmark licensing deal with Takeda for fruquintinib outside of China, bringing HUTCHMED up to US$1.13 billion, plus royalties, and demonstrating execution of the new global strategy Record Full Year 2022 oncology/immunology revenues driven by sign
Read More
HKEX Announcement (PDF)LSE RNS Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 27 Feb 2023

HUTCHMED Completes Patient Enrollment of Phase II Registration Trial of Amdizalisib in Follicular Lymphoma in China
Hong Kong, Shanghai & Florham Park, NJ — Monday, February 27, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM, HKEX:​13) today announces that it has completed patient enrollment of Phase II registration trial of amdizalisib
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 1 Feb 2023

Monthly Return
HKEX Announcement (PDF)
Announcements & Press Releases, Group | 31 Jan 2023

HUTCHMED to Announce 2022 Final Results
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, January 31, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2022 on Tuesday, February 28, 2023 at
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 23 Jan 2023

HUTCHMED Announces License to Takeda to Develop and Commercialize Fruquintinib Outside China
— HUTCHMED to receive US$400 million upfront on deal closing and up to US$730 million in potential future milestone payments, totaling up to US$1.13 billion, plus royalties on net sales — — Marketing authorization submissions in the U.S., Eur
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 18 Jan 2023

HUTCHMED Announces Agreement with NHSA for Inclusion of ORPATHYS® in the National Reimbursement Drug List in China
Hong Kong, Shanghai & Florham Park, NJ –– Wednesday, January 18, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) today announces, following negotiations with the China National Healthcare Security Administration (
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 3 Jan 2023

Monthly Return
HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 3 Jan 2023

HUTCHMED Completes Patient Enrollment of ESLIM-01, a Phase III Trial of Sovleplenib in Primary Immune Thrombocytopenia in China
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, January 3, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM, HKEX:​13) today announces that it has completed patient enrollment of ESLIM-01, a pivotal Phase III clinical tria
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 29 Dec 2022

Blocklisting Six Monthly Return
Hong Kong, Shanghai, & Florham Park, NJ — Friday, December 30, 2022: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM; HKEX: 13) announces the following blocklisting six monthly return: 1. Name of applican
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 19 Dec 2022

HUTCHMED Initiates Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Colorectal Cancer
— Company plans to complete rolling submission to the U.S. in the first half of 2023, followed by filings in Europe and Japan — — NDA is supported by global Phase III FRESCO-2 study conducted in the U.S., Europe, Japan and Australia — — F
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 2 Dec 2022

Monthly Return
HKEX Announcement (PDF)
Announcements & Press Releases, Group | 15 Nov 2022

HUTCHMED Announces Strategy to Focus on Late-Stage Pipeline Regulatory Approvals
Reprioritization accelerating path to profitability Evaluation of partnership opportunities for select late-stage assets   Hong Kong, Shanghai & Florham Park, NJ — Tuesday, November 15, 2022: HUTCHMED (China) Limited (“HUTCHMED”)
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 14 Nov 2022

HUTCHMED Announces Positive Topline Result in Fruquintinib Phase III FRUTIGA Study in Second-Line Gastric Cancer in China
— Results of dual primary endpoint study showed statistically significant and clinically meaningful benefit in progression-free survival, a primary endpoint — — Overall survival, the other primary endpoint, was not statistically significant
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 1 Nov 2022

Monthly Return
HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 27 Oct 2022

HUTCHMED Initiates a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China
Hong Kong, Shanghai & Florham Park, NJ — Thursday, October 27, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase II/III trial of fruquintinib in combination with sintilimab a
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 21 Oct 2022

Vesting of awards under the Long Term Incentive Plan
Hong Kong, Shanghai & Florham Park, NJ — Friday, October 21, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) announces that the non-performance based awards granted under the Long Term Incentive Plan (“LTIP”) on O
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 10 Oct 2022

HUTCHMED Initiates a Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
Hong Kong, Shanghai & Florham Park, NJ –– Monday, October 10, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase II/III trial of sovleplenib in adult patients with warm anti
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 3 Oct 2022

Monthly Return
HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 30 Sep 2022

Total Voting Rights
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 14 Sep 2022

Grant of Share Options under Share Option Scheme and Awards under Long Term Incentive Plan
Hong Kong, Shanghai, & Florham Park, NJ: Wednesday, September 14, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) announces that on September 13, 2022, it granted share options under the Share Option Scheme adopted by
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 8 Sep 2022

HUTCHMED Highlights Phase III FRESCO-2 MRCT Data Summary of Fruquintinib in Refractory Metastatic Colorectal Cancer from the Upcoming ESMO 2022 Presentation
— Fruquintinib treatment reduced the risk of death by 34% in metastatic colorectal cancer (0.66 HR) — — Increased disease control with risk of disease progression or death reduced by 68% (0.32 HR) — — Results to be presented in a late-b
Read More
View Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 1 Sep 2022

Monthly Return
HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 23 Aug 2022

TR-1: Standard form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:
Read More
HKEX Announcement (PDF)LSE RNS Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 23 Aug 2022

HUTCHMED Highlights Fruquintinib MRCT FRESCO-2 Data to be Presented at the Upcoming ESMO Congress 2022
— Trial met primary endpoint of overall survival and all secondary endpoints — — Selected as a late-breaker presentation — — Conference call and webcast to be held on Monday, September 12 at 2:00 pm Paris time to review the presentation a
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 9 Aug 2022

Inmagene and HUTCHMED Announce First Participant in Global Phase I Trial of IMG-004
San Diego, Shanghai and Hong Kong — Tuesday, August 9, 2022: Inmagene Biopharmaceuticals ("Inmagene") and HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) announce today that the first participant, based in the United State
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 8 Aug 2022

HUTCHMED Announces that Fruquintinib Global Phase III FRESCO-2 Study Has Met Its Primary Endpoint in Metastatic Colorectal Cancer
— Trial met primary endpoint of overall survival and all secondary endpoints — — Overall safety consistent with fruquintinib known profile — — Plans for regulatory submissions underway in the U.S., Europe and Japan — — Results to
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 8 Aug 2022

HUTCHMED and AstraZeneca Announce that TAGRISSO® Plus Savolitinib Demonstrated 49% Objective Response Rate in Lung Cancer Patients with High Levels of MET Overexpression and/or Amplification in SAVANNAH Phase II Trial
— MET is the most common biomarker in patients with EGFR-mutated lung cancer who develop resistance to targeted therapy — — Global SAFFRON Phase III trial evaluating this combination is underway —   Hong Kong, Shanghai & Florh
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 2 Aug 2022

Monthly Return
HKEX Announcement (PDF)
Announcements & Press Releases, Group | 1 Aug 2022

HUTCHMED Reports 2022 Interim Results and Provides Business Updates
Oncology/Immunology revenues up 113% to $91.1 million, due to ELUNATE®, SULANDA® and ORPATHYS® growth First presentation of SAVANNAH data showing 52% response rate and 9.6 month duration of response in 2L+ post-TAGRISSO® NSCLC1 patients with hig
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 1 Aug 2022

HUTCHMED Initiates a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China
Hong Kong, Shanghai & Florham Park, NJ — Monday, August 1, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that it has initiated a bridging study of tazemetostat in China. The first patient receiv
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
1234
5
6789101112131415161718